Skin Cancer Treatment in India & UAE

Expert skin cancer treatment — Mohs surgery for basal and squamous cell carcinoma, immunotherapy for melanoma, and targeted BRAF inhibitors. Compare costs in India and UAE.

Estimated cost: $2,000 – $6,000 · Average stay: 3–7 days

Skin cancer is the most common malignancy in the world, with over 1.5 million new cases of melanoma diagnosed annually and many millions more of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma). The three main types require distinctly different treatment approaches, ranging from simple excision for early non-melanoma cancers to sophisticated combination immunotherapy for advanced melanoma.

The prognosis for skin cancer is highly stage-dependent. Basal cell carcinoma is rarely life-threatening and is cured in over 99% of cases with appropriate local treatment. Squamous cell carcinoma has an excellent prognosis when treated early, though high-risk subtypes can spread to lymph nodes. Melanoma, the most aggressive skin cancer, has seen its prognosis transform dramatically since the introduction of immune checkpoint inhibitors (pembrolizumab, nivolumab) and BRAF-targeted therapies — with 5-year survival rates for advanced melanoma rising from under 10% a decade ago to over 40–50% today.

India and the UAE offer expert dermatologic oncology services combining experienced surgical oncologists, board-certified dermatologists trained in Mohs surgery, and medical oncologists who administer the latest immunotherapy and targeted therapy regimens. Treatment costs are 60–80% lower than Western markets, with the same drugs and surgical standards.

Types of Skin Cancer: Basal Cell, Squamous Cell, and Melanoma

Three skin cancers account for the vast majority of cases:

Basal cell carcinoma (BCC) is the most common skin cancer. It arises from basal cells in the deepest layer of the epidermis and grows slowly. BCC rarely metastasizes but can cause significant local destruction if neglected. Treatment is highly effective with Mohs surgery, excision, or radiation.

Squamous cell carcinoma (SCC) arises from squamous cells in the outer epidermis. It can spread to regional lymph nodes and, rarely, to distant organs. Risk factors include ultraviolet exposure, immunosuppression, and human papillomavirus. Early-stage SCC is cured with surgery or radiation in over 90% of cases.

Melanoma arises from pigment-producing melanocytes. Despite representing fewer than 5% of skin cancers, melanoma causes the majority of skin cancer deaths. It spreads aggressively to lymph nodes and distant organs. Stage I–II melanoma is managed with wide local excision and sentinel lymph node biopsy. Stage III–IV melanoma requires systemic therapy — immunotherapy and/or BRAF/MEK-targeted therapy.

Who Needs Skin Cancer Treatment?

Any confirmed skin cancer diagnosis warrants treatment. The urgency and type of treatment depend on the cancer type and stage.

For basal cell and squamous cell carcinoma: Any confirmed biopsy result indicating BCC or SCC requires excision or Mohs surgery. Most cases are managed in outpatient settings under local anesthesia. High-risk SCCs with perineural invasion, deep tissue extension, or lymph node involvement require more aggressive treatment including sentinel node biopsy, lymph node dissection, and adjuvant radiation.

For melanoma: Stage I–II melanoma requires wide excision with sentinel lymph node biopsy. Patients with positive sentinel nodes (stage III) receive complete lymph node dissection or radiation and adjuvant immunotherapy (pembrolizumab or nivolumab for 12 months) or targeted therapy (dabrafenib + trametinib for BRAF V600-mutant melanoma). Stage IV (metastatic) patients receive combination immunotherapy (nivolumab + ipilimumab) or BRAF-targeted therapy.

Skin Cancer Surgery and Systemic Treatment

Surgical excision is the cornerstone of treatment for all skin cancers. The extent of surgery depends on the cancer type, location, and stage.

Mohs micrographic surgery is the gold standard for facial and cosmetically sensitive BCC and high-risk SCC. The surgeon removes the tumor layer by layer, examining each layer under the microscope immediately, and continues only until all margins are confirmed clear. Mohs achieves the highest cure rate (99% for primary BCC) while removing the minimal amount of normal tissue.

Wide local excision with adequate surgical margins (0.5–2 cm for melanoma, depending on depth) is performed under local or general anesthesia. Sentinel lymph node biopsy is performed simultaneously for melanomas thicker than 0.8 mm.

For advanced and metastatic melanoma, systemic therapy — immunotherapy and/or targeted therapy — forms the backbone of treatment. Pembrolizumab (200 mg every 3 weeks) is the preferred frontline option regardless of BRAF status in metastatic melanoma.

Procedure Steps

1. Biopsy with full histopathology: excisional biopsy for suspected melanoma; shave or punch biopsy for suspected BCC/SCC.
2. Staging for melanoma: sentinel lymph node biopsy; PET-CT or CT for stage II–IV disease; BRAF mutation testing.
3. Wide local excision or Mohs surgery: performed under local or general anesthesia depending on size and location.
4. Sentinel lymph node biopsy for melanoma: nuclear medicine lymphoscintigraphy followed by intraoperative gamma probe-guided node removal.
5. For stage III melanoma: complete lymph node dissection or targeted radiation to the node basin.
6. Adjuvant systemic therapy (stage III–IV): pembrolizumab, nivolumab, or dabrafenib + trametinib for 12 months.
7. Reconstruction: skin grafting or flap repair for large defects after Mohs or wide excision.
8. Surveillance: clinical skin examination every 3–6 months; imaging every 6–12 months for higher-stage disease.

Types of Skin Cancer Treatment

Mohs Micrographic Surgery

Layer-by-layer surgical removal with immediate intraoperative margin examination under the microscope. Achieves 99% cure rate for primary BCC and high-risk SCC while maximally preserving normal tissue. Ideal for facial and functionally sensitive areas.

Cost: $800 – $3,000

Wide Local Excision + Sentinel Node Biopsy

Surgical removal of melanoma with recommended safety margins (1–2 cm) combined with sentinel lymph node mapping and biopsy to detect microscopic nodal spread. The standard operation for stage I–III melanoma.

Cost: $2,500 – $6,000

Pembrolizumab / Nivolumab (Checkpoint Immunotherapy)

PD-1 checkpoint inhibitor immunotherapy that unleashes the immune system to attack melanoma cells. First-line treatment for advanced melanoma regardless of BRAF status. Durable responses in 30–40% of patients, including some complete remissions.

Cost: $1,500 – $4,000 per cycle

BRAF + MEK Inhibitor Therapy

Dabrafenib + trametinib (or vemurafenib + cobimetinib) combination targeted therapy for BRAF V600E-mutant melanoma. Produces rapid tumor shrinkage in most patients. Used as adjuvant therapy in stage III disease and as first-line option in BRAF-mutant stage IV disease.

Cost: $2,000 – $5,000 per month

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

India — $2,000 – $6,000 — Save 65–80%

UAE — $4,000 – $10,000 — Save 50–65%

USA / UK — $12,000 – $40,000+ — Baseline

Skin cancer treatment in India is 65–80% less expensive than in the United States. Mohs surgery costs are a fraction of Western prices. Immunotherapy drugs such as pembrolizumab and nivolumab are available at significantly reduced cost through biosimilar programs and government-negotiated pricing. International patients can access the same molecular diagnostics, drugs, and surgical expertise at dramatically lower out-of-pocket expense.

Recovery & Follow-up

Recovery after Mohs surgery or wide excision is rapid. Most outpatient excisions allow return to light activity within 24–48 hours. Wound healing takes 1–3 weeks depending on size and reconstruction. Sentinel node biopsy adds 1–3 days to hospital stay. For patients on adjuvant immunotherapy, infusions are administered every 3 weeks for 12 months on an outpatient basis. Common immunotherapy side effects — fatigue, skin rash, joint pain — are generally manageable and monitored closely.

Recovery Tips

• Keep the surgical site clean and dry for the first 48 hours; change dressings as instructed.
• Use sun protection (SPF 50+, hats, UV-protective clothing) diligently — sun exposure is the primary modifiable risk factor for skin cancer recurrence.
• Report any new pigmented lesions, changing moles, or skin growths promptly for evaluation.
• If on immunotherapy, attend all infusion appointments and promptly report immune-related symptoms: rash, diarrhea, cough, or fatigue.
• Maintain regular skin surveillance examinations every 3–6 months with your dermatologic oncologist.

Risks & Complications

Risks of excisional surgery include bleeding, infection, scarring, and — in Mohs surgery — rare recurrence even with clear margins. Sentinel node biopsy risks include lymphedema (rare), seroma, and nerve injury. Immunotherapy risks include immune-related adverse events affecting the skin, gut, lungs, liver, and endocrine glands — most of which are reversible with early steroid treatment. BRAF/MEK therapy can cause fever, rash, secondary skin cancers, and cardiac effects. All patients receive comprehensive risk counseling before treatment.

Why GAF Healthcare

Gaf Healthcare connects skin cancer patients with India's and UAE's premier dermatologic oncology programs. Our partner hospitals maintain dedicated melanoma tumor boards, licensed Mohs surgeons, and medical oncologists experienced in the latest immunotherapy and targeted therapy protocols. We coordinate second opinions, molecular testing, and all logistics so you can focus entirely on your recovery.

Frequently Asked Questions

What is the cure rate for basal cell carcinoma?

Basal cell carcinoma has a cure rate exceeding 99% when treated with Mohs surgery or wide excision. Even recurrent BCC after prior treatment has a 95%+ cure rate with Mohs micrographic surgery.

Can melanoma be cured?

Stage I and II melanoma is cured in 80–95% of patients with surgery alone. Stage III melanoma has a 5-year survival of 40–78% with modern adjuvant immunotherapy. Stage IV melanoma is rarely cured, but durable long-term remissions occur in 15–25% of patients on combination immunotherapy.

What is the cost of pembrolizumab (Keytruda) in India?

Pembrolizumab biosimilars are available in India at approximately $800–$1,500 per infusion compared to $10,000+ per infusion in the USA. This represents an enormous cost advantage for international patients seeking advanced melanoma treatment.

How long is the hospital stay for skin cancer surgery?

Mohs surgery and simple wide excision are outpatient procedures — no overnight stay required. Wide excision with sentinel lymph node biopsy requires 1–2 days. Lymph node dissection requires 3–5 days of hospitalization.

Does skin cancer treatment in India use the same drugs as in the US?

Yes. India's premier cancer centers administer the same checkpoint inhibitors (pembrolizumab, nivolumab) and BRAF inhibitors (dabrafenib, vemurafenib) used at leading US cancer centers, often through licensed biosimilars or direct pharmaceutical supply, at a fraction of the cost.